1. 1. Achrol A, Rennert R, Anders C, Soffietti R, S. Ahluwalia M, Nayak L, et al. (2019) Brain metastases. Nat Rev Dis Primers, 5: 5. [DOI:10.1038/s41572-018-0055-y] [PMID]

2. van den Bent M (2003) The role of chemotherapy in brain metastases. Eur J Cancer, 39: 2114-2120. [DOI:10.1016/S0959-8049(03)00577-X] [PMID]

3. Gremmer R, Schröder M, ten Huinink W, Brandsma D, Boogerd W (2008) Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. J Neurooncol, 90: 335-339. [DOI:10.1007/s11060-008-9668-4] [PMID]

4. Goldstein D and Berkowitz R (2012) Current management of gestational trophoblastic neoplasia. Hematol Oncol Clin North Am, 26: 111-131. [DOI:10.1016/j.hoc.2011.10.007] [PMID]

5. Chao J, Phillips R, Nickson J (1954) Roentgen-ray therapy of cerebral metastases. Cancer, 7: 682-689 https://doi.org/10.1002/1097-0142(195407)7:4<682::AID-CNCR2820070409>3.0.CO;2-S [DOI:10.1002/1097-0142(195407)7:43.0.CO;2-S] [PMID]

6. Andrews D, Scott C, Sperduto P, et al. (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet, 363: 1665-1672. [DOI:10.1016/S0140-6736(04)16250-8] [PMID]

7. Bezjak A, Adam J, Panzarella T, Levin W, Barton R, Kirkbride P, et al. (2001) Radiotherapy for brain metastases: defining palliative response. Radiother Oncol, 61: 71-76. [DOI:10.1016/S0167-8140(01)00426-1] [PMID]

8. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. (1997) Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 37: 745-751 [DOI:10.1016/S0360-3016(96)00619-0] [PMID]

9. Kim E, Wustenberg R, Rubsam A, Schmitz-Salue C, Warnecke G, Bücker E, et al. (2010) Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-Oncology, 12: 389-40010. [DOI:10.1093/neuonc/nop046] [PMID] []

10. Briceño E, Calderon A, Sotelo J (2007) Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol, 67: 388-391. [DOI:10.1016/j.surneu.2006.08.080] [PMID]

11. Sotelo J, Briceño E, López-González M (2006) Adding chloroquine to conventional treatment for glioblastoma multiforme. Ann Intern Med, 144: 337. [DOI:10.7326/0003-4819-144-5-200603070-00008] [PMID]

12. Marmor M, Kellner U, Lai T, Lyons J, Mieler W (2011) Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy Ophthalmol, 118: 415-422. [DOI:10.1016/j.ophtha.2010.11.017] [PMID]

13. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. (English Edition) Actas Dermosifiliogr, 112: 90-92. https://doi.org/10.1016/j.ad.2019.05.009 [DOI:10.1016/j.adengl.2019.05.021] [PMID]

14. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R (1981) Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys, 7: 1633-1638. https://doi.org/10.1016/0360-3016(81)90370-9 [DOI:10.1016/0360-3016(81)90184-X]

15. Davey P, Hoegler D, Ennis M, Smith J (2008) A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol, 88: 173-176 [DOI:10.1016/j.radonc.2008.05.020] [PMID]

16. Haie-Meder C, Pellae-Cosset B, Laplanche A, Lagrange J, Tuchais C, Nogues C, et al. (1993) Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol, 26: 111-116 [DOI:10.1016/0167-8140(93)90091-L] [PMID]

17. Murray K, Scott C, Greenberg H, Emami B, Seider M, Vora N, et al. (1997) A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the radiation therapy oncology group (RTOG) 9104. Int J Radiat Oncol Biol Phys, 39: 571-574. [DOI:10.1016/S0360-3016(97)00341-6] [PMID]

18. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, et al. (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol, 20(17): 3644-3650. [DOI:10.1200/JCO.2002.04.140] [PMID]

19. DeAngelis L, Currie V, Kim J, Krol G, O'Hehir M, Farag F, et al. (1989) The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol, 7(3): 241-7. [DOI:10.1007/BF00172917] [PMID]

20. Eyre H, Ohlsen J, Frank J, LoBuglio A, McCracken J, Weatherall T, et al. (1984) Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. J Neurooncol, 2(4): 325-330. [DOI:10.1007/BF00178115] [PMID]

21. Komarnicky LT, Phillips T, Martz K, Asbell S, Isaacson S, Urtasun R (1991) A randomized phase iii protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys, 20: 53-58. [DOI:10.1016/0360-3016(91)90137-S] [PMID]

22. Phillips T, Scott C, Leibel S, Rotman M, Weigensberg I (1995) Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys, 33: 339-348. [DOI:10.1016/0360-3016(95)00168-X] [PMID]

23. Mehta M, Shapiro W, Phan S, et al. (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: Results of a phase III trial. Int J Radiat Oncol Biol Phys, 73: 1069-1076. [DOI:10.1016/j.ijrobp.2008.05.068] [PMID]

24. Scott C, Suh J, Stea B, Nabid A, Hackman J (2007) Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol, 30: 580-587. [DOI:10.1097/COC.0b013e3180653c0d] [PMID]

25. Suh J, Stea B, Nabid A, et al. (2006) Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases. J Clin Oncol, 24: 106-114 [DOI:10.1200/JCO.2004.00.1768] [PMID]

26. O'Neill P, Bray P, Hawley S, Ward S, Park B (1998) 4-Aminoquinolines-Past, present, and future; A chemical perspective. Pharmacol Ther, 77: 29-58. [DOI:10.1016/S0163-7258(97)00084-3] [PMID]

27. Romanelli F, Smith K, Hoven A (2004) Chloroquine and Hydroxychloroquine as Inhibitors of Human Immunodeficiency Virus (HIV-1) Activity. Curr Pharm Des, 10: 2643-2648. [DOI:10.2174/1381612043383791] [PMID]

28. Katz S and Russell A (2011) Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol, 23: 278-281. [DOI:10.1097/BOR.0b013e32834456bf] [PMID]

29. Eldredge H, DeNittis A, DuHadaway J, Chernick M, Metz R, Prendergast G (2013) Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial. Radiat Oncol J, 2: 315-321. [DOI:10.1007/s13566-013-0111-x] [PMID] []

30. Rojas-Puentes L, Gonzalez-Pinedo M, Crismatt A, Ortega-Gomez A, Gamboa-Vignolle C, Nuñez-Gomez R, Dorantes-Gallareta Y, Arce-Salinas C, Arrieta O (2013) Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases. Radiat Oncol, 8: 209. [DOI:10.1186/1748-717X-8-209] [PMID] []

31. Brazil L, Swampillai A, Mak K, et al. (2018) P01.072 Hydroxychloroquine and short course radiotherapy for elderly patients with glioma: a randomised study. Neuro Oncol, 20: iii246-iii246. [DOI:10.1093/neuonc/noy139.114] []